Venus Remedies tied up with Israel-based generic drug maker Teva

Sep 2, 2014 11:30 IST

Pharmaceutical firm Venus Remedies tied up with Israel-based generic drug maker Teva on 1 September 2014 for selling an anti- cancer drug in the Canadian market.

Details of the collaborative agreement
• Initially, Venus Remedies would be manufacturing the anti- cancer drug at its research unit Venus Medicine Research Centre for assisting Teva in registrations.
• Thereafter, Venus will assist Teva in enhancing the business from this drug in the Canadian market through its manufacturing capabilities.
• Teva will use the infrastructure and regulatory competence of Venus for the commercialization of this anti-cancer product in the Canadian market
• This association will help Venus capture a sizeable market share for this product in the first year of the agreement.

The anti-cancer drug

The high-potential drug is under patent protection till 2016. The drug is mainly used for the treatment of malignant pleural mesothelioma and non-squamous non-small cell lung cancer.

The market size of this anti-cancer drug in Canada is 75-100 million US dollars.

Is this article important for exams ? Yes22 People Agreed
Read more Current Affairs on: Venus Remedies , Teva , Canadian market

DISCLAIMER: JPL and its affiliates shall have no liability for any views, thoughts and comments expressed on this article.

Latest Videos

Register to get FREE updates

    All Fields Mandatory
  • (Ex:9123456789)
  • Please Select Your Interest
  • Please specify

  • ajax-loader
  • A verifcation code has been sent to
    your mobile number

    Please enter the verification code below

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK